Black Hairy Tongue Associated with Erlotinib Treatment in a Patient with Advanced Lung Cancer
Annals of Dermatology
;
: 526-528, 2011.
Artículo
en Inglés
| WPRIM
| ID: wpr-29024
ABSTRACT
Erlotinib is a tyrosine kinase inhibitor that acts on the epidermal growth factor receptor (EGFR). There have been many reports of the mucocutaneous side effects related to several EGFR inhibitors (EGFRIs). However, no case of black hairy tongue (BHT) associated with EGFRI has been reported. Herein, we report the first case of erlotinib-induced BHT in a 61-year-old man with advanced lung cancer. Considering recent use of EGFRIs worldwide, dermatologists should recognize the possible occurrence of BHT associated with EGFRIs such as erlotinib.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Quinazolinas
/
Lengua Vellosa
/
Proteínas Tirosina Quinasas
/
Hidroxitolueno Butilado
/
Receptores ErbB
/
Clorhidrato de Erlotinib
/
Pulmón
/
Neoplasias Pulmonares
Límite:
Humanos
Idioma:
Inglés
Revista:
Annals of Dermatology
Año:
2011
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS